Traditional Chinese medicine enterprise brand accelerate development

Medicine observers

Core clew: the development of traditional Chinese medicine "1025" plan "points out, establish Chinese medicine inheritance innovation system, science and technology to improve the contribution of traditional Chinese medicine industry development; Improve the research development and rational utilization of ability, strengthen the traditional Chinese medicine industry innovation ability, and improve the international competitiveness of the industry of Chinese market. At the same time, supervise the government at all levels increase in Chinese medicine driving force for the development of the career, increase the investment in Chinese medicine, Chinese medicine career for a good environment for development.

According to the planning of the index, to 2015, traditional Chinese medicine is expected to industrial output will reach 559 billion yuan RMB, the annual growth rate of 12%.

Research and development enterprises "golden period"

Data showed that in 2011, the national Chinese medicine yinpian industry business income reached RMB 85.372 billion, compared with 2006 compound annual growth rate above 35%; Traditional Chinese medicine achieve production 2.426 million tons, compared with 2003 the year compound growth of around 18.78%, Chinese traditional medicine in the production and sales strong momentum, Chinese traditional medicine industry overall good condition. On this basis, the planning "come on stage, will further accelerate the development of the industry, especially with the specific index's advancement, the governments at all levels will also expand service channel of traditional Chinese medicine, Chinese medicine industry to provide basis for support.

Meanwhile, analysts say, "planning" will make proprietary Chinese medicine research and development dynamics get more attention to innovation, all kinds of traditional Chinese medicine and modern Chinese medicine brand listed enterprise will enter the golden development. Among them, the Chinese herbal medicine resources, has strong modern pharmaceutical technology and brand development ability of the enterprise is expected to achieve sustained and rapid development. For example essence pharmaceutical production JiDeSheng out snake tablets and produced derivatives such as toilet water, relieving itching spray, produced the donkey-hide gelatine donge donkey-hide gelatine series, health products, etc. This kind of brand development ability, it has advantage of brand of Chinese medicine enterprise, is easy to break through the pure medicine bound, effectively expand brand value coverage, the space of market potential is tremendous.

In addition, some unique formula of raw materials and traditional Chinese medicine enterprise development momentum brand also cannot be ignored. As to our country of the Chinese national spirit and the rare have sole development advantage with force of medicine, the spirit and the industrialization has just started; And JiZheng and pharmacology of production XiaoTong TieGao curative effect obvious advantages, in the orthopaedic painkillers to keep the lead. This kind of enterprise are all expected to become a leader in the industry of Chinese medicine golden development.

New drug approval in chains

Although r&d type Chinese medicine brand enterprise development is strong, but there are still some factors restricting the development. Data shows that at present the Chinese herbal medicine new medicine by registered there are 1141 species, one of these new drugs accounted for 11.5%, 2 kinds of 6.5%, three or four kind of 40%, 5 kinds of 2%. Data reflect, a number of kinds of new distinctness lack, low level repeat is serious, the whole industry development level downturn, strong r&d type Chinese medicine enterprise deficient.

The expert points out, the main factors caused this phenomenon, in Chinese herbal medicine new medicine the limitations of the examination and approval system. Different and western medicine, Chinese traditional medicine has its own particularity. Although Chinese medicine in clinical treatment effect significantly, overwhelmingly; But if the western medicine for the research of traditional Chinese medicine most of failed the examination and approval. However, after the success of the new drug development, must have the approval certificate to produce the market, or even efficacy again good, apply for patent is meaningless. According to the examination and approval system for Chinese herbal medicine new medicine, no matter the party, gu fang, pays according to western medicine for examination and approval must be method and requirements of the mandatory for extracting active ingredient, so that the Chinese traditional medicine development must first consider easy for extracting active ingredient and through the examination and approval. The enterprise research and development for the Chinese medicine can't break through the difficult problem, hindered the development of traditional Chinese medicine research and development type enterprise transformation.

To this, the people in the industry say, from a government perspective, although at present had good related policies, but should also be in Chinese medicine to examination and approval of the easing policy; And as the enterprise itself should strengthen traditional Chinese medicine research and development on science and technology, to the technology research, such as modeled on a bezoar pure in heart pill increasing investment ideas to improve forms of the breakthrough new drug development through.